GSK Abandons Plans For Anemia Drug Launch In Europe

Looking To Avoid Mistakes Of The Past

 
• By Andrew McConaghie
  
EMA
The EMA's medicines committee recommended daprodustat, but GSK withdrew its filing because of limited commercial potential. • Source: Getty Images
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip